Sociedad Americana de Hirudoterapia

A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition

Research article published in Journal of thrombosis and thrombolysis (2008)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Observational studyGenómica y proteómicaDesarrollo de fármacosFarmacología salivalMo W et al. · Journal of thrombosis and thrombolysis, 2008

Abstract

BACKGROUND: Hirudin is an anti-coagulative product of the salivary glands of the medicinal leech Hirudo medicinalis. It is a powerful and specific thrombin inhibitor. Peptides containing the RGD motif competitively inhibit the binding of fibrinogen to GP IIb/IIIa on the platelets, thus inhibiting platelet aggregation. RESULTS: We have constructed a recombinant RGD-hirudin (r-RGD-hirudin) by fusing the tripeptide RGD sequence to the native hirudin (wt-hirudin). The r-RGD-hirudin was expressed at high levels in Pichia pastoris, and was purified to approximately 97% homogeneity. The specific anti-thrombin activity of purified r-RGD-hirudin is 12,000 ATU/mg, which is equivalent to wt-hirudin, but only r-RGD-hirudin can inhibit platelet aggregation. The biological effects of r-RGD-hirudin on Thrombin Time (TT), Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT), Bleeding Time (BT), maximum platelet aggregation (PAGm) induced by ADP were studied in rabbit model and compared with that of wt-hirudin. The rabbits were infused r-RGD-hirudin had prolonged TT, PT, and aPTT which were similar to that of wt-hirudin; but only r-RGD-hirudin was capable of inhibiting PAGm. Histopathological analyses showed that r-RGD-hirudin was two to three times more effective than wt-hirudin in preventing thrombosis. CONCLUSIONS: r-RGD-hirudin can potentially be used as a novel anti-coagulant for the prevention of thrombosis after carotid artery anastomosis or in other thrombotic events.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsAnticoagulantsBleeding TimeHirudinsMalePichiaPlasmidsPlatelet AggregationProtein EngineeringRabbitsRecombinant ProteinsThrombin

Resumen

Hirudin is an anti-coagulative product of the salivary glands of the medicinal leech Hirudo medicinalis.

Por qué esto importa para la hirudoterapia

This study constructed a recombinant RGD-hirudin by fusing an RGD tripeptide to native hirudin from Hirudo medicinalis, expressed it in Pichia pastoris, and evaluated its dual anticoagulant and anti-platelet activities in rabbits. The r-RGD-hirudin retained equivalent anti-thrombin activity (12,000 ATU/mg) to wild-type hirudin while uniquely inhibiting ADP-induced platelet aggregation, and was two to three times more effective in preventing thrombosis histopathologically. This is relevant to ASH's domain as it engineers an enhanced bifunctional derivative of a leech-derived anticoagulant. However, this is a preclinical animal study with no leeches or hirudotherapy involved; the molecule is a recombinant fusion construct rather than a natural leech secretion component.

Citación

A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition

Mo W et al. · Journal of thrombosis and thrombolysis, 2008

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.